ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,142.15
-0.06%
Dow Jones
38,591.72
0.01%
Gold vs US Dollar
2,313.125
-0.85%
Brent Oil
82.91
0.96%
Bitcoin
65,397.82
-1.86%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. KalVista Pharmaceuticals Inc (KALV)

  7. KalVista Pharmaceuticals Inc (KALV) News

KalVista Pharmaceuticals (KALV)

KalVista Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:KALV
DateTimeSourceHeadlineSymbolCompany
10/06/202423:42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KALVKalVista Pharmaceuticals Inc
06/06/202411:30Business WireKalVista Pharmaceuticals Presents Data at Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024NASDAQ:KALVKalVista Pharmaceuticals Inc
04/06/202411:30Business WireKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KALVKalVista Pharmaceuticals Inc
03/06/202411:30Business WireKalVista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024NASDAQ:KALVKalVista Pharmaceuticals Inc
31/05/202421:09Business WireKalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary AngioedemaNASDAQ:KALVKalVista Pharmaceuticals Inc
31/05/202417:15Business WireKalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary AngioedemaNASDAQ:KALVKalVista Pharmaceuticals Inc
24/05/202421:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KALVKalVista Pharmaceuticals Inc
24/05/202421:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KALVKalVista Pharmaceuticals Inc
24/05/202411:30Business WireKalVista Pharmaceuticals Announces Ten Abstracts Accepted for Presentation at the European Academy of Allergy and Clinical Immunology Congress 2024NASDAQ:KALVKalVista Pharmaceuticals Inc
21/05/202422:59Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KALVKalVista Pharmaceuticals Inc
21/05/202422:58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KALVKalVista Pharmaceuticals Inc
21/05/202422:57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KALVKalVista Pharmaceuticals Inc
21/05/202422:55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KALVKalVista Pharmaceuticals Inc
21/05/202411:30Business WireKalVista Pharmaceuticals to Present at Upcoming Investor ConferencesNASDAQ:KALVKalVista Pharmaceuticals Inc
02/05/202411:30Business WireKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KALVKalVista Pharmaceuticals Inc
01/05/202411:30Business WireKalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal YearNASDAQ:KALVKalVista Pharmaceuticals Inc
22/04/202411:30Business WireKalVista Pharmaceuticals Appoints William C. Fairey to Board of DirectorsNASDAQ:KALVKalVista Pharmaceuticals Inc
03/04/202411:30Business WireKalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:KALVKalVista Pharmaceuticals Inc
02/04/202411:30Business WireKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KALVKalVista Pharmaceuticals Inc
18/03/202410:30Business WireKalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference AmericasNASDAQ:KALVKalVista Pharmaceuticals Inc
12/03/202410:30Business WireKalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for SebetralstatNASDAQ:KALVKalVista Pharmaceuticals Inc
11/03/202420:37Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KALVKalVista Pharmaceuticals Inc
11/03/202420:26Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KALVKalVista Pharmaceuticals Inc
11/03/202410:30Business WireKalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational UpdateNASDAQ:KALVKalVista Pharmaceuticals Inc
08/03/202421:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KALVKalVista Pharmaceuticals Inc
08/03/202411:30Business WireKalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference AmericasNASDAQ:KALVKalVista Pharmaceuticals Inc
07/03/202411:38Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KALVKalVista Pharmaceuticals Inc
07/03/202411:30Business WireKalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive OfficerNASDAQ:KALVKalVista Pharmaceuticals Inc
06/03/202411:30Business WireKalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma ConferenceNASDAQ:KALVKalVista Pharmaceuticals Inc
04/03/202411:30Business WireKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KALVKalVista Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:KALV

Your Recent History

LSE
BT.A
Bt
LSE
LLOY
Lloyds Banking
LSE
EEE
Empire Metals
LSE
PANR
Pantheon Resources
LSE
VAST
Vast Resources
LSE
ARCM
Arc Minerals
LSE
THG
Thg
LSE
POS
Plexus
LSE
GKP
Gulf Keystone Petroleum
LSE
SOLG
Solgold
LSE
SDRY
Superdry
LSE
LBE
Longboat Energy
LSE
BIRD
Blackbird
LSE
GOLD
LSE
KEFI
Kefi Gold And Copper
LSE
TERN
Tern
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved